Our main goal is to play an influential role—and minimize risk—in the search for and development of cures for brain disease. To achieve that, we collaborate broadly and deeply. We work with everyone who cares about brain diseases, from privately owned and publicly traded companies to researchers, universities, MRI manufacturers, and investors.
Here are some of our ongoing collaborations:
We are ready and able to collaborate with biopharma companies in any country and at any clinical stage.
Clinical research organizations (CROs)
We offer our biopharma clients a seamless experience by partnering with preclinical and clinical CROs—including yours.
Imeka has received the support of many investors in the past 10 years—a testimony to our value.
Université de Sherbrooke (UdS)
Imeka co-founders Maxime Descoteaux and Pierre-Marc Jodoin are also professors who lead labs at the UdS.
Sherbrooke Connectivity Imaging Lab (SCIL)
We work closely with the SCIL and they with us; in essence the SCIL helps us develop state-of-the art methods and algorithms.
Academics and researchers
We have helped further groundbreaking research by collaborating with academics and researchers.